AIM

#4754
AIM ImmunoTech Inc. Common Stock
0.3 9 USD
-7.14%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
0.39
0.39
Range Annuel
0.21
20.35
Changement quotidien
-7.14%
Changement Mensuel
-23.54%
Evolution sur 6 mois
-75.65%
Changement Annuel
-95.41%
Clôture Précédente
0.4 2
Open
0.3 9
Low
0.3 9
High
0.3 9
Volume
233
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 5.68 M
  • Employee 21
  • Founded N/A
  • CEO N/A
  • Website www.aimimmuno.com
  • Headquarter Delaware, United States
  • FIGI BBG000JL6Z80
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-0.13
ratio cours/chiffre d'affaires
20.76

AIM ImmunoTech Inc. Common Stock

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.

Nouvelles